AACT/ABAT Journal Club April 2021: The physo-stigma enigma, what’s the “DRYL”? Enduring
Mr pencil

How would you like your name to appear on your certificate?

By completing this form, you attest that you have attended the activity in its entirety.
Was the educational content of value to you?
Was the educational content scientifically sound?
If no, please explain...
Did you perceive any commercial bias or influence in the educational content?
If yes, please explain...
Did this activity improve your Skills or Strategy?
If yes, how...
Do you think what you learned will benefit you in your practice?
If yes, how...
Tell us what was good or bad about any part of the educational activity, content, speakers, materials, anything
What questions are you having in your practice that you would like to see addressed in an educational activity?
PHARMACISTS: If you do not provide your NABP ID AND your DATE OF BIRTH, your hours will not be uploaded to CPE Monitor.
(CPE Monitor) NABP e-Profile ID (ePID) - Example 123456:
(CPE Monitor) Date of Birth (MM/DD) - Example September 24 would be 0924: 
Please rate Serena A. Huntington
Content/Teaching Methods
Relevance of Content to Objectives
Independence, Objectivity, Balance, Scientific Rigor
Please rate Varun Vohra
Independence, Objectivity, Balance, Scientific Rigor
Relevance of Content to Objectives
Content/Teaching Methods
Were the learning objectives met?
Describe the adverse effects associated with physostigmine administration.
Describe the effectiveness of physostigmine in treating anticholinergic delirium in diphenhydramine ingestions.
Appraise the utility of physostigmine compated to benzodiazepines for the acute management of patients with antimuscarinic delirium and agitation.
Describe the safety and efficacy of physostigmine bolus and infusion for the control of antimuscarinic delirium and agitation.
When you viewed this webinar, were you in a group or by yourself?
If in a group, with how many people?
Mr question